ArticleProceedings of the National Academy of Sciences of the United States of America2012
A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Cell-Free Expression of Nipah Virus Transmembrane Proteins for Proteoliposome Vaccine Design.ACS nano · 2025Article
- Reversible Control of Gene Expression by Guest-Modified Adenosines in a Cell-Free System via Host-Guest Interaction.Journal of the American Chemical Society · 2024Article
- Cell-Free Protein Synthesis: A Promising Option for Future Drug Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Effective Biophysical Modeling of Cell Free Transcription and Translation Processes.Frontiers in bioengineering and biotechnology · 2020Article
- M-protein based vaccine induces immunogenicity and protection fromNPJ vaccines · 2020Article
- Streamlining the preparation of "endotoxin-free" ClearColi cell extract with autoinduction media for cell-free protein synthesis of the therapeutic protein crisantaspase.Synthetic and systems biotechnology · 2019Article
- Synthetic Biology Goes Cell-Free.BMC biology · 2019Review
- Short DNA containing χ sites enhances DNA stability and gene expression in E. coli cell-free transcription-translation systems.Biotechnology and bioengineering · 2017Article
- The growing impact of lyophilized cell-free protein expression systems.Bioengineered · 2017Review
- Cell-sized mechanosensitive and biosensing compartment programmed with DNA.Chemical communications (Cambridge, England) · 2017Article
- A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.Scientific reports · 2017Article
- Cell-Free Synthetic Biology: Engineering Beyond the Cell.Cold Spring Harbor perspectives in biology · 2016Review
- Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potent transmission-blocking immunity.Clinical and vaccine immunology : CVI · 2014Article
- Article
- Vaccine design: emerging concepts and renewed optimism.Current opinion in biotechnology · 2013Review
- Antibody-based therapeutics for the treatment of human B cell malignancies.Current allergy and asthma reports · 2013Review
- Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.Clinical & developmental immunology · 2013Review
- Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.Frontiers in oncology · 2012Article
- The promise of the anti-idiotype concept.Frontiers in oncology · 2012Article
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Clinical studies of idiotype (Id) vaccination in patients with lymphoma have established a correlation between the induced anti-Id antibody responses and favorable clinical outcomes. To streamline the production of an Id vaccine, we engineered a small diabody (Db) molecule containing both a B-cell-targeting moiety (anti-CD19) and a lymphoma Id. This molecule (αCD19-Id) was designed to penetrate lymph nodes and bind to noncognate B cells to form an antigen presentation array. Indeed, the αCD19-Id molecule accumulated on B cells in vivo after s.c. administration. These noncognate B cells, decorated with the diabody, could then stimulate the more rare Id-specific B cells. Peptide epitopes present in the diabody linker augmented the response by activating CD4(+) helper T cells. Consequently, the αCD19-Id molecule induced a robust Id-specific antibody response and protected animals from tumor challenge. Such diabodies are produced in a cell-free protein expression system within hours of amplification of the specific Ig genes from the B-cell tumor. This customized product can now be available to vaccinate patients before they receive other, potentially immunosuppressive, therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.